Efficacy and safety of rituximab for minors with immune thrombocytopenia: a systematic review and meta-analysis.
Efficacy and safety of rituximab for minors with immune thrombocytopenia: a systematic review and meta-analysis.
复制标题
利妥昔单抗对患有免疫性血小板减少症的未成年人的疗效和安全性：系统评价和荟萃分析
DOI：
10.1177/0300060520962348
复制
发表时间：
2020-10
期刊：
影响因子：
--
通讯作者：
Zhou ZP
中科院分区：
文献类型：
--
作者：
Qu M;Zhou J;Yang SJ;Zhou ZP
目的综述利妥昔单抗（RTX）治疗儿童免疫性血小板减少症（ITP）的相关研究，以阐明RTX的有效性和安全性。方法通过检索PubMed、科克伦图书馆、Web of Science、奥维德：EMBASE数据库和ClinicalTrials. gov，收集RTX治疗儿童ITP的前瞻性临床试验。采用非随机研究方法学指数量表，并进行敏感性分析。结果5项研究共100例患者，合并OR、CR、PR、SR、R和ADR率为52%（95% CI：0.36-0.77，I2 = 78%），52%（95% CI：0.41-0.67，I2 = 45%），18%（95% CI：0.10-0.33，I2 = 33%）、43%（95% CI：0.29-0.63，I2 = 0%）、25%（95% CI：0.06-0.96，I2 = 52%）和30%（95% CI：0.15-0.58，I2 = 64%）。结论RTX作为ITP患儿的二线治疗方案可能优于脾切除术，但其有效性和安全性尚需进一步的高质量临床试验验证，如随机对照试验。
Objective We reviewed relevant research on rituximab (RTX) treatment for pediatric immune thrombocytopenia (ITP) to elucidate the efficacy and safety of RTX. Methods Prospective clinical trials of RTX for the treatment of pediatric ITP were collected by searching the PubMed, Cochrane Library, Web of Science, and OVID: EMBASE databases and ClinicalTrials.gov. We examined rates of overall response (OR), complete response (CR), partial response (PR), sustained response (SR), relapse (R), and adverse drug reaction (ADR). The Methodological Index for Nonrandomized Studies scale was used, and sensitivity analyses were performed. Results For five studies, including 100 patients, the pooled OR, CR, PR, SR, R, and ADR rates were 52% (95% CI: 0.36–0.77, I2 = 78%), 52% (95% CI: 0.41–0.67, I2 = 45%), 18% (95% CI: 0.10–0.33, I2 = 33%), 43% (95% CI: 0.29–0.63, I2 = 0%), 25% (95% CI: 0.06–0.96, I2 = 52%), and 30% (95% CI: 0.15–0.58, I2 = 64%), respectively. Conclusion There is evidence, albeit low quality, that RTX may be a better second-line therapy than splenectomy for children with ITP; however, its efficacy and safety need to be validated by further high-quality clinical trials, such as randomized controlled trials.
登录
查看更多内容
影响因子：
11.1
作者：
Dierickx, D.;Verhoef, G.;Delannoy, A.
通讯作者：
Delannoy, A.
影响因子：
1.7
作者：
Slim, K;Nini, E;Chipponi, J
通讯作者：
Chipponi, J
影响因子：
1.7
作者：
Ansari, Sh;Rostami, T.;Ramim, T.
通讯作者：
Ramim, T.
DOI：
10.1016/j.jpeds.2017.08.036
发表时间：
2017-12
期刊：
The Journal of pediatrics
影响因子：
--
作者：
Oved JH;Lee CSY;Bussel JB
通讯作者：
Bussel JB
影响因子：
12.8
作者：
Zaja, Francesco;Volpetti, Stefano;Fanin, Renato
通讯作者：
Fanin, Renato